What is the Investigator Databank?

A global collaboration amongst Janssen, Lilly, Merck, Pfizer and Novartis that is maintained by third party (DrugDev.org), the Investigator Databank lets investigators grant permission to pharmaceutical companies to share investigator and site information with each other (such as infrastructure details, Good Clinical Practice (GCP) training records, trial participation, and recruitment history).
 

How does the Investigator Databank benefit investigators and trial sites?

Opting in to the Investigator Databank reduces the administrative burden for trial sites, creating a range of benefits:

• Reduces individual requests for basic site information for each sponsor
• Eliminates redundant GCP training (companies see each other's GCP training records and mutually recognize courses)
• Frees up your time to focus on clinical activities
• Expands your access to clinical research opportunities by making you & your site known to a broader base of trial sponsors
   

How can I be included in the Investigator Databank?

Enter your name or e-mail address into the Investigator Databank widget to the right to view your records. You will to receive a link to opt-in, giving your consent to allow sponsor companies to share your data with one another.

Learn more at www.investigatordatabank.org.